Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGNRegeneron(REGN) Newsfilter·2024-02-02 19:30

Fourth quarter 2023 revenues increased 1% to 3.43billionversusfourthquarter2022;excludingRonapreveTM(a)(b),revenuesincreased143.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenues increased 14% Full year 2023 revenues increased 8% to 13.12 billion versus full year 2022; excluding Ronapreve(a), revenues increased 12% Fourth quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 31% to 3.22billionversusfourthquarter2022;fullyear2023Dupixentglobalnetsalesincreased333.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to 11.59 billion versus 2022 Fourth quarter 2023 U.S. net sales f ...